These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19706823)

  • 41. Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers.
    Murase K; Yanai A; Saito M; Imamura M; Miyagawa Y; Takatsuka Y; Inoue N; Ito T; Hirota S; Sasa M; Katagiri T; Fujimoto Y; Hatada T; Ichii S; Nishizaki T; Tomita N; Miyoshi Y
    Breast Cancer; 2014 Jan; 21(1):52-7. PubMed ID: 22359195
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography.
    Kato T; Shinoda J; Nakayama N; Miwa K; Okumura A; Yano H; Yoshimura S; Maruyama T; Muragaki Y; Iwama T
    AJNR Am J Neuroradiol; 2008 Jun; 29(6):1176-82. PubMed ID: 18388218
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers.
    Nishimukai A; Inoue N; Kira A; Takeda M; Morimoto K; Araki K; Kitajima K; Watanabe T; Hirota S; Katagiri T; Nakamori S; Akazawa K; Miyoshi Y
    PLoS One; 2017; 12(9):e0184508. PubMed ID: 28886153
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hormone receptor status of operable breast cancers in Indonesia: correlation with other prognostic factors and survival.
    Aryandono T; Harijadi ; Soeripto
    Asian Pac J Cancer Prev; 2006; 7(2):321-4. PubMed ID: 16839231
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ¹⁸F-Fluorodeoxyglucose uptake and clinicopathological features of recurrent or metastatic endometrial stromal sarcoma.
    Inoue K; Tsubamoto H; Kawata S; Hao H; Ikeda Y; Oku N; Hirota S
    J Obstet Gynaecol Res; 2014 Feb; 40(2):576-82. PubMed ID: 24118160
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor characteristics and metabolic quantification in carcinoma breast: An institutional experience.
    Dubey IP; Jain A; Chauhan MS; Kumar R; Agarwal S; Kishore B; Vishnoi MG; Paliwal D; John AR; Kumar N; Sharma A; Pandit AG
    Indian J Cancer; 2017; 54(1):333-339. PubMed ID: 29199717
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?
    Yang Z; Sun Y; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
    Clin Breast Cancer; 2013 Oct; 13(5):359-63. PubMed ID: 23787040
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnostic Value of ER, PR, FR and HER-2-Targeted Molecular Probes for Magnetic Resonance Imaging in Patients with Breast Cancer.
    Jin YH; Hua QF; Zheng JJ; Ma XH; Chen TX; Zhang S; Chen B; Dai Q; Zhang XH
    Cell Physiol Biochem; 2018; 49(1):271-281. PubMed ID: 30138940
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular imaging using PET for breast cancer.
    Kurihara H; Shimizu C; Miyakita Y; Yoshida M; Hamada A; Kanayama Y; Yonemori K; Hashimoto J; Tani H; Kodaira M; Yunokawa M; Yamamoto H; Watanabe Y; Fujiwara Y; Tamura K
    Breast Cancer; 2016 Jan; 23(1):24-32. PubMed ID: 25917108
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
    Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
    Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of Melatonin in Breast Carcinoma: Correlation of Expression Patterns of Melatonin-1 Receptor With Estrogen, Progesterone, and HER2 Receptors.
    Goyal R; Gupta T; Bal A; Sahni D; Singh G
    Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):518-523. PubMed ID: 31290783
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
    Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
    Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Relea Calatayud F; Muñoz Madero V; Molina Garrido MJ; León Martín AA; Cordero García JM; Pilkington Woll JP; Chacón López-Muñiz I; Palomar Muñoz A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):308-14. PubMed ID: 23084013
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
    Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
    J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The relationship between FDG uptake in PET scans and biological behavior in breast cancer.
    Shimoda W; Hayashi M; Murakami K; Oyama T; Sunagawa M
    Breast Cancer; 2007; 14(3):260-8. PubMed ID: 17690502
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk Factors Associated with Discordant Ki-67 Levels between Preoperative Biopsy and Postoperative Surgical Specimens in Breast Cancers.
    Kim HS; Park S; Koo JS; Kim S; Kim JY; Nam S; Park HS; Kim SI; Park BW
    PLoS One; 2016; 11(3):e0151054. PubMed ID: 26954364
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic Decision.
    Georgescu R; Boros M; Moncea D; Bauer O; Coros MF; Oprea A; Moldovan C; Podoleanu C; Stolnicu S
    Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):533-538. PubMed ID: 28099174
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
    Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
    J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.